Porcine Vaccine Market accounted for US$ 2.23 billion in 2020 and is estimated to be US$ 4.41 billion by 2030 and is anticipated to register a CAGR of 7.50%. The growth of huge, intensive pig operations has made effective vaccination imperative within the swine industry. This growth in size has been amid outbreaks of disease like porcine respiratory and reproductive syndrome (PRRS) and porcine epidemic diarrhea. These have caused massive losses, and effective vaccines aren't yet available. Older diseases like pleuropneumonia, erysipelas, enzootic pneumonia, proliferative enteritis, pseudorabies, and colibacillosis still persist, and classical swine fever and influenza remain as ongoing threats. The massive size of the many operations has required the introduction of mass vaccination procedures like vaccination through beverage. The present African swine fever pandemic makes the event of an efficient vaccine against this virus, a matter of urgent necessity.
The report “Global Porcine Vaccines Market, By Type (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine Influenza, Aujeszky’s Disease (AD), Porcine Circovirus Associated Disease (PCVAD), By End-User (Veterinary Hospitals & Hog Production Farm and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
· In May 2019, Hipra launched two new swine vaccines within the South Korean marketplace for regional expansion.
· In 2021, Zoetis announced the launch of CircoMax Myco, in the European Union. It is the first, and only, vaccine that includes two porcine circovirus type 2 (PCV2) genotypes (a & b), providing broader coverage against PCV2 and longest-lasting combined protection against two of the main pathogens in the global pig industry, PCV2 and Mycoplasma hyopneumoniae.
Analyst View:
The porcine vaccine market is especially driven by the demand for gelatin and pork meat, and an increase within the prevalence of swine diseases. The govt of the many countries take initiatives to determine large animal farms to supply fresh meat and poultry products to spice up the economy further contribute the expansion of the porcine vaccines market across the world. Increasing R&D investments by vaccine manufacturing companies, government initiatives, and demand for porcine meat are a number of the main factors propelling market growth. Moreover, the rising demand for meat, milk and animal proteins and growing concern over the prevalence of zoonotic diseases are factors driving the market. Vietnam is that the third largest pig meat eating country within the world, where a mean of 29.14 kg of pig meat was consumed in 2015
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141
Key Market Insights from the report:
The Global Porcine Vaccine Market accounted for US$ 2.23 billion in 2020 and is estimated to be US$ 4.41 billion by 2030 and is anticipated to register a CAGR of 7.50%. The global porcine vaccines market report segments the market on the basis of type, disease indication, end-user, and region.
· By Type, the Global Regenerative Medicine Market is segmented into Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines.
· By Disease Indication, the Global Regenerative Medicine Market is segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine Influenza, Aujeszky’s Disease (AD), Porcine Circovirus Associated Disease (PCVAD).
· By End-User, the Global Regenerative Medicine Market is segmented into Veterinary Hospitals & Hog Production Farm and Others.
· By region, the Global Regenerative Medicine Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global porcine vaccine market in terms of revenue contribution as related to that of markets in other regions. This is attributed to the increasing government funds for the development of vaccines and the presence of dominant players in the market in this region.
Competitive Landscape:
The key players operating the global porcine vaccine market involves Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale SA, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Zoetis, Inc. and Vitus Animal Health, Inc.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
